These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 14569183)

  • 1. Marginal structural models as a tool for standardization.
    Sato T; Matsuyama Y
    Epidemiology; 2003 Nov; 14(6):680-6. PubMed ID: 14569183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief Report: Doubly Robust Estimation of Standardized Risk Difference and Ratio in the Exposed Population.
    Shinozaki T; Matsuyama Y
    Epidemiology; 2015 Nov; 26(6):873-7. PubMed ID: 26275176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating causal parameters without target populations.
    Shahar E
    J Eval Clin Pract; 2007 Oct; 13(5):814-6. PubMed ID: 17824877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bounds on potential risks and causal risk differences under assumptions about confounding parameters.
    Chiba Y; Sato T; Greenland S
    Stat Med; 2007 Dec; 26(28):5125-35. PubMed ID: 17525935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of longitudinal marginal structural models.
    Bryan J; Yu Z; Van Der Laan MJ
    Biostatistics; 2004 Jul; 5(3):361-80. PubMed ID: 15208200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marginal structural models for partial exposure regimes.
    Vansteelandt S; Mertens K; Suetens C; Goetghebeur E
    Biostatistics; 2009 Jan; 10(1):46-59. PubMed ID: 18503036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marginal structural models might overcome confounding when analyzing multiple treatment effects in observational studies.
    Suarez D; Haro JM; Novick D; Ochoa S
    J Clin Epidemiol; 2008 Jun; 61(6):525-30. PubMed ID: 18471655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invited commentary: G-computation--lost in translation?
    Vansteelandt S; Keiding N
    Am J Epidemiol; 2011 Apr; 173(7):739-42. PubMed ID: 21415028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of tamoxifen in pT1a-pT1b, pN0 breast cancer.
    Livi L; Saieva C; Paiar F; Simontacchi G; Galardi A; De Luca Cardillo C; Mangoni M; Paoletti L; Ponticelli P; Biti GP
    Eur J Surg Oncol; 2007 Apr; 33(3):271-5. PubMed ID: 16831531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the Subtleties of Inverse Probability Weighting and Marginal Structural Models.
    Breskin A; Cole SR; Westreich D
    Epidemiology; 2018 May; 29(3):352-355. PubMed ID: 29384789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
    Tchou J; Hou N; Rademaker A; Jordan VC; Morrow M
    Cancer; 2004 May; 100(9):1800-6. PubMed ID: 15112259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marginal mean weighting through stratification: a generalized method for evaluating multivalued and multiple treatments with nonexperimental data.
    Hong G
    Psychol Methods; 2012 Mar; 17(1):44-60. PubMed ID: 21843003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding Marginal Structural Models for Time-Varying Exposures: Pitfalls and Tips.
    Shinozaki T; Suzuki E
    J Epidemiol; 2020 Sep; 30(9):377-389. PubMed ID: 32684529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marginal structural models: much ado about (almost) nothing.
    Shahar E; Shahar DJ
    J Eval Clin Pract; 2013 Feb; 19(1):214-22. PubMed ID: 21883715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonparametric estimation of the bivariate recurrence time distribution.
    Huang CY; Wang MC
    Biometrics; 2005 Jun; 61(2):392-402. PubMed ID: 16011685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fitting marginal structural models: estimating covariate-treatment associations in the reweighted data set can guide model fitting.
    Pullenayegum EM; Lam C; Manlhiot C; Feldman BM
    J Clin Epidemiol; 2008 Sep; 61(9):875-81. PubMed ID: 18486447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marginal structural models for the estimation of direct and indirect effects.
    VanderWeele TJ
    Epidemiology; 2009 Jan; 20(1):18-26. PubMed ID: 19234398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bias formulas for external adjustment and sensitivity analysis of unmeasured confounders.
    Arah OA; Chiba Y; Greenland S
    Ann Epidemiol; 2008 Aug; 18(8):637-46. PubMed ID: 18652982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.
    Lash TL; Gurwitz JH; Silliman RA
    J Am Geriatr Soc; 2005 Nov; 53(11):1889-96. PubMed ID: 16274369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse probability weighting and doubly robust standardization in the relative survival framework.
    Syriopoulou E; Rutherford MJ; Lambert PC
    Stat Med; 2021 Nov; 40(27):6069-6092. PubMed ID: 34523751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.